Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Has a body mass index (BMI) greater than or equal to (\>=) 18.5 and less than or equal to (\<=) 30.0 kilogram per square meter (kg/m\^2) at the Screening Visit. (Cohorts 1 to 4 only).~2. Is a nonsmoker who has not used tobacco- or nicotine-containing products (example, nicotine patch) for at least 6 months before administration of the first dose of trial drug or invasive procedure.~3. The participant either is of nonchildbearing potential, OR, if of childbearing potential, is using a highly effective method of contraception with low user dependency during the entire duration of the study.~For Cohorts 5 and 6 (Japanese participants) only:~1. Has a BMI \>=18.0 and \<= 26.0 kg/m\^2, at the Screening Visit.~Exclusion Criteria:~1. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV), or human immunodeficiency virus (HIV) antibody/antigen, at Screening.~2. Had major surgery, donated or lost 1 unit of blood (approximately 500 milliliter \[mL\]) within 4 weeks before the Screening Visit.~3. Has a history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to beer \[354 mL/12 ounces\], wine \[118 mL/4 ounces\], or distilled spirits \[29.5 mL/1 ounce\] per day).~4. Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.~5. Has a substance abuse disorder.~6. Has risk of suicide according to the investigator's clinical judgment per Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening or has made a suicide attempt in the 6 months before Screening.~7. Has luteinizing hormone (LH), follicle-stimulating hormone (FSH), or estradiol levels that are clinically abnormal.~8. Has a resting heart rate outside of the range of 50 to 100 beats per minute, confirmed on repeat testing within a maximum of 30 minutes, at the Screening Visit or Check-in (Day -1).~For Cohort 3 only (includes CSF sample collection):~1. Has had CSF collection performed within 30 days before Check-in (Day -1).~2. Has significant vertebral deformities (scoliosis or kyphosis) that, in the opinion of the investigator, may interfere with the lumbar puncture procedure.~3. Has a local infection at the puncture site.~4. Has thrombocytopenia or other suspected bleeding tendencies noted before the procedure.~5. Has developed signs and symptoms of spinal radiculopathy, including lower extremity pain and paresthesia.~6. Has any focal neurological deficit that might suggest an increase in intracranial pressure.~7. Has any abnormal finding on ophthalmological assessment/fundoscopy indicative of raised intracranial pressure (that is, optic disc swelling/edema; or \[uncontrolled\] hypertensive retinopathy).~8. Regularly has moderate-to-severe headaches requiring analgesics.~9. Has any bleeding abnormality or history of bleeding abnormalities.~10. Has abnormal coagulation tests (prothrombin time \[PT\]/international normalized ratio \[INR\], partial thromboplastin time \[PTT\]) at Screening.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Non-Japanese Cohort 1: TAK-418 120 mg and TAK-418 160 mg (Type: EXPERIMENTAL): TAK-418 120 milligram (mg) or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period A followed by a minimum of 14 days of washout period, followed by TAK-418 160 mg or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period B. The actual TAK-418 dose for Period B will be determined based on safety, tolerability, and PK data available from the previous dose in Period A.
- Non-Japanese Cohort 2: TAK-418 20 mg (Type: EXPERIMENTAL): TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days.
- Non-Japanese Cohort 3: TAK-418 40 mg (Type: EXPERIMENTAL): TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 3 will be determined based on safety, tolerability, and PK data available from the previous doses.
- Non-Japanese Cohort 4: TAK-418 60 mg (Type: EXPERIMENTAL): TAK-418 60 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 4 will be determined based on safety, tolerability, and PK data available from the previous doses.
- Japanese Cohort 5: TAK-418 20 mg (Type: EXPERIMENTAL): TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 5 will be determined based on safety, tolerability, and PK data available from the previous doses.
- Japanese Cohort 6: TAK-418 40 mg (Type: EXPERIMENTAL): TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 6 will be determined based on safety, tolerability, and PK data available from the previous doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues